NCT05290090 2023-10-17
ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL
Zhejiang Cancer Hospital
Phase 2 Unknown
Clinical Trials
16 trialsNCT05923879 2023-06-28
Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma
Ruijin Hospital
Unknown
NCT05883709 2023-06-01
A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL
Ruijin Hospital
Unknown
NCT05179733 2023-05-23
The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years
Ruijin Hospital
Phase 3 Unknown
NCT04113226 2023-02-08
Relyage
Centre Hospitalier Universitaire, Amiens
Phase 2 Unknown
NCT05575973 2022-10-12
Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Huazhong University of Science and Technology
Phase 2 Unknown
NCT05200312 2022-03-11
ZR2-CHOP
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05186558 2022-03-07
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT03837873 2022-01-26
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT03949062 2021-02-17
Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL
Ruijin Hospital
Phase 2 Unknown
NCT04025593 2020-11-19
Biomarker Guided Treatment in DLBCL
Ruijin Hospital
Phase 2 Unknown
NCT04544059 2020-09-10
Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT04432402 2020-06-16
Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Unknown
NCT02060656 2019-09-19
LEGEND
Royal Marsden NHS Foundation Trust
Phase 2 Unknown
NCT03715296 2019-07-08
Lenalidomide Based Immunotherapy in the Treatment of DLBCL
Ruijin Hospital
Unknown
NCT01307592 2014-01-10
Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown